Compare · CV vs MDT
CV vs MDT
Side-by-side comparison of CapsoVision Inc. (CV) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CV and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT carries a market cap of $138.66B.
- MDT has been more active in the news (6 items in the past 4 weeks vs 2 for CV).
- MDT has more recent analyst coverage (25 ratings vs 2 for CV).
- Company
- CapsoVision Inc.
- Medtronic plc.
- Price
- -
- -
- Market cap
- -
- $138.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 2
- 6
- Recent ratings
- 2
- 25
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest CV
- SEC Form EFFECT filed by CapsoVision Inc.
- SEC Form S-1 filed by CapsoVision Inc.
- SEC Form 3 filed by new insider Shen Ching Hang
- SEC Form 3 filed by new insider Harari Eliyahou Et Al
- SEC Form 10-K filed by CapsoVision Inc.
- CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results
- SEC Form 4 filed by Tsai Chen Lung
- SEC Form 4 filed by Kuo Hui Ying
- SEC Form 4 filed by King Wen-Herng Henry
Latest MDT
- Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
- Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease
- The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
- Medtronic to announce financial results for its fourth quarter and full fiscal year 2026
- Telix Strengthens Board with Additional Director Appointments
- Amendment: SEC Form SCHEDULE 13G/A filed by Medtronic plc.
- Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures
- Medtronic plc. filed SEC Form 8-K: Regulation FD Disclosure
- Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing